Back HBV Disease Progression

HBV Disease Progression

EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer

The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?

The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among chronic hepatitis B patients treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD Liver Meeting in Boston. However, liver cancer remains a major indication for liver transplants and has a negative effect on survival of people with hepatitis B.

alt

Read more:

Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer

A blood test that measures a set of circulating microRNAs (miRNAs) may help identify who will develop hepatitis B virus-related hepatocellular carcinoma (HCC), a type of primary liver cancer, according to research published in the May 24 online edition of OncoTarget.

alt

Read more:

AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study

Nivolumab (Opdivo), an antibody that blocks the PD-1 receptor and restores T-cell anti-tumor activity, appeared safe and was associated with disease control and stabilization in a Phase 1/2 study of patients with hepatocellular carcinoma, according to late-breaking results from the CheckMate 040 study presented at the AASLD Liver Meeting last month in Boston.

alt

Read more:

Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C

Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.

alt

Read more: